Shares of Establishment Labs Holdings Inc. (ESTA) surged 8.01% in pre-market trading on Thursday, following the company's impressive fourth-quarter earnings report and positive outlook for its entry into the US market.
The medical device company reported a robust start in the US, generating $3.3 million in sales in the first two months of the launch, exceeding initial expectations. This strong performance, coupled with a 41% increase in total revenue for Q4 to $44.5 million driven by higher production volumes and early US sales, has bolstered investor confidence.
Furthermore, Establishment Labs has successfully onboarded over 650 accounts in the US market, with 450 placing orders and an impressive 88% reordering rate, indicating strong product acceptance. The company is on track to achieve its first positive EBITDA quarter in 2025, supported by gross margin expansion and operational efficiency improvements.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。